Mock Hearing

Section 337 Exclusion Orders for New Technology: Examining Public Interest Concerns Potentially Arising from Exclusion Orders – Case Study on Biologics

June 27, 2019 3:15pm

Michael K. Milani
Managing Director
Ocean Tomo (Chicago, IL)

Tony V. Pezzano
DLA Piper LLP (New York, NY)

Jeffrey M. Telep
King & Spalding LLP (Washington, DC)

Cleve B. Tyler
Managing Director
Berkeley Research Group (Washington, DC)

  • Exploring the unique public interest issues that arise for different technologies, such as 5G mobile phone technology and biologics products
  • Understanding how the Commission has been adapting to new technologies through an increase in the issuance of tailored remedies to address unique public interest concerns
  • Examining whether the same public interest issues that could arise in cases involving biologics could be raised in cases involving biosimilars